Chem. J. Chinese Universities ›› 2020, Vol. 41 ›› Issue (5): 884.doi: 10.7503/cjcu20190714

• Review • Previous Articles     Next Articles

Recent Advances on Polyoxometalates as Metallodrug Agents for Alzheimer’s Disease

MA Mengmeng1,2,QU Xiaogang1,*()   

  1. 1. State Key Laboratory of Rare Earth Resource Utilization, Laboratory of Chemical Biology,Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
    2. College of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China
  • Received:2019-12-27 Online:2020-05-10 Published:2020-03-23
  • Contact: Xiaogang QU E-mail:xqu@ciac.ac.cn
  • Supported by:
    † Supported by the National Natural Science Foundation of China(21431007);† Supported by the National Natural Science Foundation of China(21533008);the Key Program of Frontier of Sciences, Chinese Academy of Sciences(QYZDJ-SSW-SLH052)

Abstract:

Alzheimer’s disease(AD) is a progressive neurodegenerative disorder characterized by cognitive dysfunction and memory loss. Although the exact pathogenesis of AD remains unclear, recent evidences have demonstrated that the accumulation and deposition of β-amyloid peptide(Aβ) is a key step in AD pathogenesis. Polyoxometalates(POMs) have the merits of adjustable structures, ease of preparation, and low cost, and thus have shown promising in AD treatment. Hence, recent advances on the POMs as a novel AD metallodrug agent are summarized.

Key words: Alzheimer’s disease, Polyoxometalates, β-Amyloid

CLC Number: 

TrendMD: